THE PROBLEM

Diabetes is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years.

Just in the United States:

Approximately 1.25 million Americans have Type 1 diabetes.
By 2050, 5 million people are expected to be diagnosed with Type 1 diabetes.
An estimated 40,000 people are diagnosed with Type 1 diabetes each year.
200,000 people under the age of 20 years old have Type 1 diabetes.
Between 2011 and 2012, 17,900 children and adolescents under the age of 20 were diagnosed with Type 1 diabetes.
There was a 21% increase in people diagnosed with Type 1 diabetes between 2001 and 2009 under the age of 20.
By 2050, 600,000 people under the age of 20 are expected to have Type 1 diabetes.
Among people under the age of 20, non-Hispanic whites had the highest rates of new diagnosis of Type 1 diabetes.
There are $14 billion in Type 1 diabetes-associated healthcare expenditures and lost income each year.
Less than a third of people with Type 1 diabetes consistently achieve target blood-glucose control levels.

The Share Price (constantly updated current share price here)

As of this writing, Senseonics has an unbelievably low share price. For whatever reasons, market makers have manipulated the share price lower. This is easier to do with low volumes of trading such as Senseonics has had. This presents a MASSIVE buying opportunity for those smart enough to recognize it. For comparative purposes, we’ll show you a historical chart for a competitor, Dexcom. You’ll see that in 2009 Dexcom was trading at around $1.36. It’s now trading at over $200! If you had invested $10,000 in Dexcom at that time, your investment would now be worth over $1.5 Million. If you didn’t catch it at the bottom, and you bought at 5 times that price ($6.80), your $10,000 would now be worth $300.000. Even if you bought it at 10 times the low price ($13.60), your $10k investment would be worth over $150k. Clearly, the sooner you bought in (when the risk and uncertainty was higher), the more exponential your return. But even at $50 or $100, Dexcom was clearly a fantastic investment at the time.

We believe Senseonics is as big of an opportunity as Dexcom was in 2009, with a better product and even more potential.

Loading stock data...

The Potential For Growth & Sales

Here are a few main bullet points to keep in mind when evaluating your decision:

Eversense 90 day sensor is already FDA approved
The 180 day sensor has already began selling in Europe, and is currently undergoing the approval process in the US.
Eversense is being approved by more and more insurance providers all the time, and has just recently been approved by Medicare!
Eversense is also in the process of being approved for adolescents, which will make the management of childhood diabetes infinitely easier, as the data can be shared with parents and care givers. No more constant finger pricks! https://clinicaltrials.gov/ct2/show/NCT03815552
The 365 day sensor is currently in development!

THE PRODUCT: EVERSENSE CGM

The current field of competitors now includes Dexcom (NASDAQ: DXCM), Medtronic(NYSE: MDT), and Abbot Laboratories (NYSE: ABT). Of these, Eversense by Senseonics is the only implantable device, allowing the sensor to be changed every 90 or 180 days (365 day sensor comingEversense is also the most accurate. For an academic comparison of the CGM alternatives, go here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468523/

Here’s a video of a comparison between Eversense and one of the main competitors, Dexcom’s G6 system:

THE OPPORTUNITY

We are in the midst of a sea change in medical technology. Constant Glucose Monitors (CGM for short) are the future of diabetic treatment.